Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Management of Rising PSA After Cryoablation

Introduction to Management

  • The National Comprehensive Cancer Network recommends that for a male with rising PSA after cryoablation, observation without Lupron is the most appropriate approach given his limited life expectancy, unless he has symptomatic disease or documented metastases 1

Rationale for Approach

  • Men with life expectancy less than 10 years should undergo active surveillance rather than aggressive treatment, as 5- to 10-year cancer-specific mortality is very low for most prostate cancers 1
  • At age 91, the median life expectancy is approximately 4-5 years, making the likelihood of dying from prostate cancer extremely low compared to competing causes of mortality 1
  • ADT as primary treatment for localized prostate cancer does not improve survival and is not recommended 1

Considerations for ADT

  • Lupron should only be initiated if specific high-risk features are present, such as documented metastatic disease on imaging (bone scan, CT, or PSMA PET/CT) 2, 3
  • Extremely rapid PSA doubling time (less than 3 months) suggesting aggressive biology 3
  • PSA velocity showing more than tripling in one year 3

Alternative Therapies

  • Salvage radiation therapy (SRT) after cryoablation failure may offer disease control without the systemic toxicity of ADT 4, 5
  • The addition of short-term ADT to SRT may improve progression-free survival in select cases, but this must be balanced against toxicity in a 91-year-old 5

Monitoring Strategy

  • PSA monitoring every 3-6 months to assess velocity and doubling time 3
  • Imaging only if PSA rises rapidly or symptoms develop (PSMA PET/CT is most sensitive) 4, 3